1. Sahin,U., Kariko,K. and Tureci,O. (2014) mRNA-based
therapeutics–developing a new class of drugs. Nat. Rev. Drug Discov.,
13, 759–780.
2. Schott,J.W., Morgan,M., Galla,M. and Schambach,A. (2016) Viral
and synthetic RNA vector technologies and applications. Mol. Ther.,
24, 1513–1527.
3. Pardi,N., Hogan,M.J., Porter,F.W. and Weissman,D. (2018) mRNA
vaccines - a new era in vaccinology. Nat. Rev. Drug Discov., 17,
261–279.
4. Richner,J.M., Himansu,S., Dowd,K.A., Butler,S.L., Salazar,V.,
Fox,J.M., Julander,J.G., Tang,W.W., Shresta,S., Pierson,T.C. et al.
(2017) Modified mRNA vaccines protect against zika virus infection.
Cell, 168, 1114–1125.
5. Liang,F., Lindgren,G., Lin,A., Thompson,E.A., Ols,S., Rohss,J.,
John,S., Hassett,K., Yuzhakov,O., Bahl,K. et al. (2017) Efficient
targeting and activation of antigen-presenting cells in vivo after
modified mRNA vaccine administration in Rhesus Macaques. Mol.
Ther., 25, 2635–2647.
6. Mulligan,M.J., Lyke,K.E., Kitchin,N., Absalon,J., Gurtman,A.,
Lockhart,S., Neuzil,K., Raabe,V., Bailey,R., Swanson,K.A. et al.
(2020) Phase I/II study of COVID-19 RNA vaccine BNT162b1 in
adults. Nature, 586, 589–593.
7. Baden,L.R., El Sahly,H.M., Essink,B., Kotloff,K., Frey,S.,
Novak,R., Diemert,D., Spector,S.A., Rouphael,N., Creech,C.B. et al.
(2020) Efficacy and safety of the mRNA-1273 SARS-CoV-2 vaccine.
N. Engl. J. Med., 384,403–416.
8. Yin,H., Song,C.Q., Dorkin,J.R., Zhu,L.J., Li,Y., Wu,Q., Park,A.,
Yang,J., Suresh,S., Bizhanova,A. et al. (2016) Therapeutic genome
editing by combined viral and non-viral delivery of CRISPR system
components in vivo. Nat. Biotechnol., 34, 328–333.
9. Miller,J.B., Zhang,S., Kos,P., Xiong,H., Zhou,K., Perelman,S.S.,
Zhu,H. and Siegwart,D.J. (2017) Non-viral CRISPR/Cas gene
editing in vitro and in vivo enabled by synthetic nanoparticle
co-delivery of Cas9 mRNA and sgRNA. Angew. Chem. Int. Ed Engl.,
56, 1059–1063.
10. Warren,L., Manos,P.D., Ahfeldt,T., Loh,Y.H., Li,H., Lau,F.,
Ebina,W., Mandal,P.K., Smith,Z.D., Meissner,A. et al. (2010) Highly
efficient reprogramming to pluripotency and directed differentiation
of human cells with synthetic modified mRNA. Cell Stem Cell, 7,
618–630.
11. Poleganov,M.A., Eminli,S., Beissert,T., Herz,S., Moon,J.I.,
Goldmann,J., Beyer,A., Heck,R., Burkhart,I., Barea Roldan,D. et al.
(2015) Efficient reprogramming of human fibroblasts and
blood-derived endothelial progenitor cells using nonmodified RNA
for reprogramming and immune evasion. Hum. Gene Ther., 26,
751–766.
12. Miki,K., Endo,K., Takahashi,S., Funakoshi,S., Takei,I.,
Katayama,S., Toyoda,T., Kotaka,M., Takaki,T., Umeda,M. et al.
(2015) Efficient detection and purification of cell populations using
synthetic microRNA switches. Cell Stem Cell, 16, 699–711.
13. Endo,K., Hayashi,K. and Saito,H. (2019) Numerical operations in
living cells by programmable RNA devices. Sci. Adv., 5, eaax0835.
14. Garneau,N.L., Wilusz,J. and Wilusz,C.J. (2007) The highways and
byways of mRNA decay. Nat. Rev. Mol. Cell Biol., 8, 113–126.
15. Jemielity,J., Fowler,T., Zuberek,J., Stepinski,J., Lewdorowicz,M.,
Niedzwiecka,A., Stolarski,R., Darzynkiewicz,E. and
Rhoads,R.E. (2003) Novel “anti-reverse” cap analogs with superior
translational properties. RNA, 9, 1108–1122.
16. Grudzien-Nogalska,E., Jemielity,J., Kowalska,J., Darzynkiewicz,E.
and Rhoads,R.E. (2007) Phosphorothioate cap analogs stabilize
mRNA and increase translational efficiency in mammalian cells.
RNA, 13, 1745–1755.
17. Strenkowska,M., Kowalska,J., Lukaszewicz,M., Zuberek,J., Su,W.,
Rhoads,R.E., Darzynkiewicz,E. and Jemielity,J. (2010) Towards
mRNA with superior translational activity: synthesis and properties
of ARCA tetraphosphates with single phosphorothioate
modifications. New J. Chem., 34, 993–1007.
18. Rydzik,A.M., Warminski,M., Sikorski,P.J., Baranowski,M.R.,
Walczak,S., Kowalska,J., Zuberek,J., Lukaszewicz,M., Nowak,E.,
TD,W.C. et al. (2017) mRNA cap analogues substituted in the
tetraphosphate chain with CX2: identification of O-to-CCl2 as the
first bridging modification that confers resistance to decapping
without impairing translation. Nucleic Acids Res., 45, 8661–8675.
Downloaded from https://academic.oup.com/nar/article/51/6/e34/7023930 by Kyoto Daigaku Bungakubu Toshokan user on 12 April 2023
various methods for modifying the RNA chain or 3 end.
Our method introduces the functional group orthogonal to
those reactions at the 5 site so that multiple site-selective
RNA modifications may be possible. We believe that 5 end
modification by VCE will become a versatile and useful
method for producing various types of functional RNAs in
RNA engineering and nanotechnology fields (48,49).
In conclusion, we show that various cap-modified RNAs
can be prepared easily and efficiently by using VCE and
GTP analogs. Modified dinucleotide cap analogs are useful for synthesizing various modified-capped RNAs cotranscriptionally. However, it is necessary to chemically synthesize the dinucleotide cap analog to introduce rare modifications. In contrast, our VCE-based method can generate cap-modified mRNAs that exhibit various translation levels using commercially available materials without
chemically-synthesized dinucleotides. Modified caps containing azide groups, amino groups, and alkynes can also
be easily synthesized, making it possible to use this method
as a 5 end-specific modification method for RNA. This
cap-modification method using the capping enzyme or the
capping enzyme in combination with bioconjugation techniques will enable the generation of functional mRNAs with
non-natural cap modifications and provide useful tools for
the fields of RNA therapeutics and biological research.
Nucleic Acids Research, 2023, Vol. 51, No. 6 e34
e34 Nucleic Acids Research, 2023, Vol. 51, No. 6
36. De la Pena,M., Kyrieleis,O.J.P. and Cusack,S. (2007) Structural
insights into the mechanism and evolution of the vaccinia virus
mRNA cap N7 methyl-transferase. EMBO J., 26, 4913–4925.
37. Hillen,H.S., Bartuli,J., Grimm,C., Dienemann,C., Bedenk,K.,
Szalay,A.A., Fischer,U. and Cramer,P. (2019) Structural basis of
poxvirus transcription: transcribing and capping vaccinia complexes.
Cell, 179, 1525–1536.
38. Kocmik,I., Piecyk,K., Rudzinska,M., Niedzwiecka,A.,
Darzynkiewicz,E., Grzela,R. and Jankowska-Anyszka,M. (2018)
Modified ARCA analogs providing enhanced translational
properties of capped mRNAs. Cell Cycle, 17, 1624–1636.
39. Kowalska,J., Lewdorowicz,M., Zuberek,J., Grudzien-Nogalska,E.,
Bojarska,E., Stepinski,J., Rhoads,R.E., Darzynkiewicz,E.,
Davis,R.E. and Jemielity,J. (2008) Synthesis and characterization of
mRNA cap analogs containing phosphorothioate substitutions that
bind tightly to eIF4E and are resistant to the decapping
pyrophosphatase DcpS. RNA, 14, 1119–1131.
40. Kore,A.R., Shanmugasundaram,M., Charles,I., Cheng,A.M. and
Barta,T.J. (2007) Synthesis and application of 2’-fluoro-substituted
cap analogs. Bioorg. Med. Chem. Lett., 17, 5295–5299.
41. Shanmugasundaram,M., Charles,I. and Kore,A.R. (2016) Design,
synthesis and biological evaluation of dinucleotide mRNA cap
analog containing propargyl moiety. Bioorg. Med. Chem., 24,
1204–1208.
42. Mamot,A., Sikorski,P.J., Warminski,M., Kowalska,J. and
Jemielity,J. (2017) Azido-Functionalized 5’ Cap Analogues for the
Preparation of Translationally Active mRNAs Suitable for
Fluorescent Labeling in Living Cells. Angew. Chem. Int. Ed Engl., 56,
15628–15632.
43. Holstein,J.M., Anhauser,L. and Rentmeister,A. (2016) Modifying
the 5’-Cap for click reactions of eukaryotic mRNA and to tune
translation efficiency in living cells. Angew. Chem. Int. Ed Engl., 55,
10899–10903.
44. Cohen,S.B. and Cech,T.R. (1997) Dynamics of thermal motions
within a large catalytic RNA investigated by cross-linking with
thiol-disulfide interchange. J. Am. Chem. Soc., 119, 6259–6268.
45. Warminski,M., Sikorski,P.J., Warminska,Z., Lukaszewicz,M.,
Kropiwnicka,A., Zuberek,J., Darzynkiewicz,E., Kowalska,J. and
Jemielity,J. (2017) Amino-functionalized 5’ Cap analogs as tools for
site-specific sequence-independent labeling of mRNA. Bioconjug.
Chem., 28, 1978–1992.
46. Ziemniak,M., Szabelski,M., Lukaszewicz,M., Nowicka,A.,
Darzynkiewicz,E., Rhoads,R.E., Wieczorek,Z. and
Jemielity,J. (2013) Synthesis and evaluation of fluorescent cap
analogues for mRNA labelling. RSC Adv., 3, 20943–20958.
47. Bednarek,S., Madan,V., Sikorski,P.J., Bartenschlager,R., Kowalska,J.
and Jemielity,J. (2018) mRNAs biotinylated within the 5’ cap and
protected against decapping: new tools to capture RNA-protein
complexes. Philos. Trans. R. Soc. Lond. B Biol. Sci., 373, 20180167.
48. Jasinski,D., Haque,F., Binzel,D.W. and Guo,P. (2017) Advancement
of the emerging field of RNA nanotechnology. ACS Nano, 11,
1142–1164.
49. Afonin,K.A., Dobrovolskaia,M.A., Church,G. and Bathe,M. (2020)
Opportunities, barriers, and a strategy for overcoming translational
challenges to therapeutic nucleic acid nanotechnology. ACS Nano,
14, 9221–9227.
Downloaded from https://academic.oup.com/nar/article/51/6/e34/7023930 by Kyoto Daigaku Bungakubu Toshokan user on 12 April 2023
19. Issur,M., Bougie,I., Despins,S. and Bisaillon,M. (2013) Enzymatic
synthesis of RNAs capped with nucleotide analogues reveals the
molecular basis for substrate selectivity of RNA capping enzyme:
impacts on RNA metabolism. PLoS One, 8, e75310.
20. Martin,S.A. and Moss,B. (1976) mRNA guanylyltransferase and
mRNA (guanine-7-)-methyltransferase from vaccinia virions. Donor
and acceptor substrate specificites. J. Biol. Chem., 251, 7313–7321.
21. Fuchs,A.L., Neu,A. and Sprangers,R. (2016) A general method for
rapid and cost-efficient large-scale production of 5’ capped RNA.
RNA, 22, 1454–1466.
22. Bougie,I. and Bisaillon,M. (2004) The broad spectrum antiviral
nucleoside ribavirin as a substrate for a viral RNA capping enzyme.
J. Biol. Chem., 279, 22124–22130.
23. Martin,F., Barends,S., Jaeger,S., Schaeffer,L., Prongidi-Fix,L. and
Eriani,G. (2011) Cap-assisted internal initiation of translation of
histone H4. Mol. Cell, 41, 197–209.
24. Gunawardana,D., Domashevskiy,A.V., Gayler,K.R. and
Goss,D.J. (2015) Efficient preparation and properties of mRNAs
containing a fluorescent cap analog: anthraniloyl-m(7)GpppG.
Translation (Austin), 3, e988538.
25. Ettwiller,L., Buswell,J., Yigit,E. and Schildkraut,I. (2016) A novel
enrichment strategy reveals unprecedented number of novel
transcription start sites at single base resolution in a model
prokaryote and the gut microbiome. BMC Genomics, 17, 199.
26. Suzuki,T., Ikeuchi,Y., Noma,A., Suzuki,T. and Sakaguchi,Y. (2007)
Mass spectrometric identification and characterization of
RNA-modifying enzymes. Methods Enzymol., 425, 211–229.
27. Ohira,T., Minowa,K., Sugiyama,K., Yamashita,S., Sakaguchi,Y.,
Miyauchi,K., Noguchi,R., Kaneko,A., Orita,I., Fukui,T. et al. (2022)
Reversible RNA phosphorylation stabilizes tRNA for cellular
thermotolerance. Nature, 605, 372–379.
28. Ohira,T. and Suzuki,T. (2016) Precursors of tRNAs are stabilized by
methylguanosine cap structures. Nat. Chem. Biol., 12, 648–655.
29. Lin,H., Miyauchi,K., Harada,T., Okita,R., Takeshita,E.,
Komaki,H., Fujioka,K., Yagasaki,H., Goto,Y.I., Yanaka,K. et al.
(2018) CO2-sensitive tRNA modification associated with human
mitochondrial disease. Nat. Commun., 9, 1875.
30. Debets,M.F., Van Berkel,S.S., Dommerholt,J., Dirks,A.J.,
Rutjes,F.P.J.T. and Van Delft,F.L. (2011) Bioconjugation with
strained alkenes and alkynes. Accounts Chem Res, 44, 805–815.
31. Kyrieleis,O.J., Chang,J., de la Pena,M., Shuman,S. and
Cusack,S. (2014) Crystal structure of vaccinia virus mRNA capping
enzyme provides insights into the mechanism and evolution of the
capping apparatus. Structure, 22, 452–465.
32. York,J.L. (1981) Effect of the structure of the glycon on the
acid-catalyzed hydrolysis of adenine nucleosides. J. Org. Chem., 46,
2171–2173.
33. Gates,K.S., Nooner,T. and Dutta,S. (2004) Biologically relevant
chemical reactions of N7-alkylguanine residues in DNA. Chem. Res.
Toxicol., 17, 839–856.
34. Kowalska,J., Wypijewska del Nogal,A., Darzynkiewicz,Z.M.,
Buck,J., Nicola,C., Kuhn,A.N., Lukaszewicz,M., Zuberek,J.,
Strenkowska,M., Ziemniak,M. et al. (2014) Synthesis, properties,
and biological activity of boranophosphate analogs of the mRNA
cap: versatile tools for manipulation of therapeutically relevant
cap-dependent processes. Nucleic Acids Res., 42, 10245–10264.
35. Zheng,S. and Shuman,S. (2008) Structure-function analysis of
vaccinia virus mRNA cap (guanine-N7) methyltransferase. RNA, 14,
696–705.
PAGE 16 OF 16
...
論文の公開元へ
